M&As this week: Biomx, Pace Analytical Services, Millendo Therapeutics

22nd December 2017 (Last Updated December 22nd, 2017 00:00)

Israel-based microbiome drug discovery company Biomx has announced the acquisition of biotechnology company Rondinx. 

Israel-based microbiome drug discovery company Biomx has announced the acquisition of biotechnology company Rondinx.

The acquisition will expand BiomX’s therapeutic pipeline and is intended to strengthen its product development pipeline.

Contract development and analytical testing laboratory Pace Analytical Services has acquired contract research organisation Wolfe Laboratories.

The acquisition enables the two companies to expand their contract drug development services to the life science industry.

Both the acquirer and target companies are based in the US.

Millendo Therapeutics has purchased Alize Pharma SAS in a stock-based transaction.

"The $399.72m acquisition will enable JSR to expand its contract research and development capabilities."

The target company will be renamed Millendo Therapeutics in the US and as Millendo Therapeutics SAS in France and the rest of Europe.

The acquisition enables clinical-stage biopharmaceutical company Millendo to address the unmet patient requirements in rare endocrine diseases.

Taiwanese drug discovery and development services company CrownBio has signed a merger agreement with Japanese chemical manufacturing company JSR and Gallo Merger Sub Corp.

The TWB12bn ($399.72m) acquisition will enable JSR to expand its contract research and development capabilities.

Fujifilm Corp has agreed to acquire 11.7% stake in US-based genome-editing company EdiGene Corporation through a series A investment of ¥470m ($4.17m).

The acquisition will enable the Japanese imaging and information solutions provider to manufacture gene therapy drugs.